Moreover, a next-generation sequencing analysis of 17 recurrent and 13 non-recurrent meningiomas identified three CDKN2A alteration (p.Ala148Thr) mutation, whole homozygous or heterozygous gene loss, or promotor methylation (>8) strongly correlated with recurrence and a Ki67 labeling index > 7% [51]. Here, CDKN2A is linked to meningioma.